Tagged with Research

Denmark Alphalyse is a Danish contract research organization (CRO) specialising in protein chemistry, mass spectrometry, and bioinformatics. The firm’s co-founder & COO Ejvind Mørtz outlines its journey since its foundation in 2005, the evolution of the specialist CRO space, and the significance of AI and data integration.   The advantage of…

China The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval designations have been awarded since 2015. Elsewhere, Pfizer is utilising drone technology to promote health education in remote areas and…

Turkey Prof. Hasan Mandal, president of the Scientific and Technological Research Council of Turkey (TÜBİTAK), explains how the COVID-19 platform coordinated by the agency has transformed the Turkish ecosystem by bringing together 436 researchers from 49 different institutions to collaborate on 17 drug and vaccine development projects. In addition, Prof. Mandal…

Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…

Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…

Europe The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching above their weight. This data is taken from the 2021 edition of the EFPIA’s comprehensive annual data review of the European pharma…

Denmark Boehringer Ingelheim’s Nicolas Dumoulin outlines Denmark’s relevance to the German family-owned company, including the strong uptake of its diabetes and COPD medications in the country and its host of research collaborations with local partners.   There is a wealth of knowledge in Denmark, especially in the cardiometabolic area, and a…

Denmark Healthcare DENMARK is a non-profit organization and public-private partnership representing Danish healthcare stakeholders internationally. Jakob Skaarup Nielsen, its CEO, highlights the Nordic country’s “treasure trove” of health data, the efforts to digitalize even further and the population’s open mind when it comes to participating in clinical trials. Moreover, he outlines…

Europe Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the innovative European pharma industry in building a healthier future for the continent’s citizens in the wake of the COVID-19 pandemic.…

Turkey Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for a revision of the good clinical practice guidelines. Moreover, he explains why TITCK becoming an International Council for Harmonisation (ICH)…

Singapore IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs in the region differ from their counterparts in the US and Europe, and the most important digitalisation trends to emerge from the COVID-19 pandemic.   Almost 50 percent…

Singapore Professor Ashok Venkitaraman introduces his work in Singapore, coordinating and catalysing research on the causes of cancer in Asia, and translating this research to clinical impact through improved detection, treatment and prevention. Professor Venkitaraman also outlines how the Singaporean research ecosystem compares to that of his former base in Cambridge,…